ALOX12–12-HETE pathway was activated in liver IRI and its activation was further enhanced in NAFLD, which induced more severe HCC recurrence in fatty livers than normal livers. Here, ALOX12 is linked to metabolic dysfunction-associated steatotic liver disease.